Market Overview

ARIAD Announces Updated Clinical Results on AP26113 in Patients with Non-Small Cell Lung Cancer

ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated
clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113,
in patients with advanced non-small cell lung cancer (NSCLC) from an
ongoing Phase 1/2 trial. The study confirms compelling clinical evidence
of the anti-tumor activity of AP26113 at multiple dose levels in
patients with anaplastic lymphoma kinase positive (ALK+) NSCLC,
including brain metastases, and initial clinical evidence of anti-tumor
activity in patients with epidermal growth factor receptor mutant
(EGFRm) NSCLC.

The study identified a recommended Phase 2 dose of 180 mg administered
orally once daily. The Phase 2 portion of the trial is now open and
enrolling patients at

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (ARIA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free